Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors

American Journal of Therapeutics

Volumn 14, Issue 5, 2007, Pages 438-441

  Chuang, Peale ^a   Langone, Anthony J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ezetimibe; HMG CoA reductase inhibitors; Hyperlipidemia; Immunosuppressive medications; Renal transplantation

Indexed keywords

ATORVASTATIN; CYCLOSPORIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; HYPERLIPIDEMIA; KIDNEY TRANSPLANTATION; LIPID ABSORPTION; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34748910062     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000209693.83065.a6     Document Type: Article

References (23)

1. Bumgardner GL, Wilson GA, Tso PL, et al. Impact of serum lipids on long-term graft and patient survival after renal transplantation. Transplantation. 1995;60:1418-1421.
2. Garthwaite, EA, Will EJ, Bartlett C, et al. Patient-specific prompts in the cholesterol management of renal transplant outpatients: Results and analysis of underperformance. Transplantation. 2004;78:1042-1047.
3. Tse KC, L MF, Yip PS, et al. A long-term study on hyperlipidemia in stable renal transplant recipients. Clin Transplant. 2004;18:274-280.
4. Garcia I, Errasti P, Lavilla FJ, et al. Effects of cerivastatin in dyslipemia and other cardiovascular risk factors after renal transplantation. Transplant Proc. 2002;34:401-402.
5. Yoshimura N, Oka T, Okamoto M, et al. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation. 1992;53:94-99.
6. Cofan F, Gilabert R, Zambon D, et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplant Proc. 2002;34:384-388.
7. Holdaas H, Fellstrom B, Jardine AG, et al. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024-2031.
8. Knopp RH, Gitter H, Truitt T, et al. Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729-741.
9. Dujovne CA, Ettinger MP, McNeer JF, et al. Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092-1097.
10. Ballantyne CM, Houri J, Notarbartolo A, et al. Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation. 2003;107:2409-2415.
11. Stein E, Stender S, Mata P, et al. Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004;148:447-455.
12. Kerzner B, Corbelli J, Sharp S, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol. 2003;91:418-424.
13. Melani L, Mills R, Hassman D, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J. 2003;24:717-728.
14. Feldman T, Koren M, Insull W Jr, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004;93:1481-1486.
15. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125-2134.
16. Goldberg AC, Sapre A, Liu J, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79:620-629.
17. Ezetimibe package insert. Kenilworth, NJ: Merck/Schering-Plough Pharmaceuticals; 2005.
18. Kohnle M, Pietruck F, Kribben A, et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant. 2006;6:205-208.
19. Puthenparumpil JJ, Keough-Ryan T, Kiberd M, et al. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc. 2005;37:1033-1035.
20. Guichard SW. Nutrition in the kidney transplant recipient. In: Danovitch GM, ed. Handbook of Kidney Transplantation. Philadelphia: Lippincott Williams & Wilkins; 2001:394-410.
21. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
22. Tziajka PE, Reis M, Kreul S, et al. Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe. Am J Cardiol. 2004;93:779-780.
23. Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation. 2006;81:804-807.